Waldmann T A, Morell A G, Wochner R D, Strober W, Sternlieb I
J Clin Invest. 1967 Jan;46(1):10-20. doi: 10.1172/JCI105502.
Ceruloplasmin labeled with (67)copper and administered intravenously to dogs, control human subjects, and patients with excessive gastrointestinal loss was shown to fulfill the requirements for a label for quantification of gastrointestinal protein loss. The radiocopper moiety was poorly absorbed from the gastrointestinal tract, not actively secreted into the intestinal tract, and did not alter significantly the metabolism of ceruloplasmin. Approximately 70% of the body pool of ceruloplasmin in both dog and man was within the intravascular space. In control human subjects the mean ceruloplasmin concentration was 30 mg per 100 ml with total circulating and total body ceruloplasmin pools of 15.5 and 22 mg per kg, respectively. In patients with excessive gastrointestinal protein loss secondary to intestinal lymphangiectasia, the serum ceruloplasmin concentration was reduced to 16 mg per 100 ml with a comparable reduction in the total circulating and total body ceruloplasmin pools to 8.8 and 12 mg per kg. The survival half-time of ceruloplasmin was 6.1 days in normal human subjects and 4.5 days in normal dogs. From 1.0 to 1.9% of the intravascular pool of ceruloplasmin was lost into the gastrointestinal tract of the dog per day, representing less than 11% of the over-all metabolism of this protein. In control human subjects from 1.9 to 3.9% of the intravascular pool was lost into the gastrointestinal tract each day, representing a maximum of from 11 to 22% of the over-all metabolism of this molecule. In contrast, patients with intestinal lymphangiectasia had a markedly shortened ceruloplasmin survival of 3.1 days, with from 15 to 40% of the intravascular pool of ceruloplasmin cleared into the gastrointestinal tract daily. This represented 76% of the over-all metabolism of this protein. Thus, although bulk loss of serum proteins into the gastrointestinal tract does not normally appear to be a significant factor in protein metabolism in normal dogs and men, such loss is a major factor in the pathogenesis of the hypoceruloplasminemia noted in patients with intestinal lymphangiectasia.
用(67)铜标记并静脉注射给犬、健康对照者及胃肠道蛋白过度丢失患者的铜蓝蛋白,被证明符合用于量化胃肠道蛋白丢失的标记物要求。放射性铜部分从胃肠道吸收不良,不主动分泌至肠道,且未显著改变铜蓝蛋白的代谢。犬和人的铜蓝蛋白体内池约70%存在于血管内空间。在健康对照者中,铜蓝蛋白平均浓度为每100 ml 30 mg,循环总铜蓝蛋白池和全身总铜蓝蛋白池分别为每千克15.5 mg和22 mg。在因肠淋巴管扩张继发胃肠道蛋白过度丢失的患者中,血清铜蓝蛋白浓度降至每100 ml 16 mg,循环总铜蓝蛋白池和全身总铜蓝蛋白池相应降至每千克8.8 mg和12 mg。铜蓝蛋白在正常人体中的存活半衰期为6.1天,在正常犬中为4.5天。犬每天有1.0%至1.9%的血管内铜蓝蛋白池丢失至胃肠道,占该蛋白总体代谢的不到11%。在健康对照者中,每天有1.9%至3.9%的血管内池丢失至胃肠道,占该分子总体代谢的最多11%至22%。相比之下,肠淋巴管扩张患者的铜蓝蛋白存活期明显缩短至3.1天,每天有15%至40%的血管内铜蓝蛋白池清除至胃肠道。这占该蛋白总体代谢的76%。因此,虽然血清蛋白大量丢失至胃肠道在正常犬和人中通常似乎不是蛋白质代谢的重要因素,但这种丢失是肠淋巴管扩张患者低铜蓝蛋白血症发病机制中的一个主要因素。